Amrutanjan Health Care Limited (AMRUTANJAN.BO)
INR 629.4
(3.05%)
INR 629.4
(3.05%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 13.96 Million INR | 245.74% |
| 2022 | 4.04 Million INR | 30.07% |
| 2021 | 3.1 Million INR | -55.81% |
| 2020 | 7.02 Million INR | -37.08% |
| 2019 | 11.16 Million INR | 0.0% |
| 2018 | - INR | 0.0% |
| 2017 | - INR | 0.0% |
| 2016 | - INR | 0.0% |
| 2015 | - INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2013 | - INR | 0.0% |
| 2012 | - INR | -100.0% |
| 2011 | 61.11 Million INR | 65.3% |
| 2010 | 36.97 Million INR | 167.85% |
| 2009 | 13.8 Million INR | 320.45% |
| 2008 | 3.28 Million INR | -96.12% |
| 2007 | 84.67 Million INR | 10.16% |
| 2006 | 76.86 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 13.96 Million INR | 0.0% |
| 2023 FY | 13.96 Million INR | 245.74% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 3.71 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 4.04 Million INR | 30.07% |
| 2022 Q4 | 4.04 Million INR | 0.0% |
| 2022 Q2 | 1.76 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 3.1 Million INR | -55.81% |
| 2021 Q2 | 3.82 Million INR | 0.0% |
| 2021 Q4 | 3.1 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 7.02 Million INR | -37.08% |
| 2020 Q2 | 9.98 Million INR | 0.0% |
| 2020 Q4 | 7.02 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 11.16 Million INR | 0.0% |
| 2019 Q2 | 11.86 Million INR | 0.0% |
| 2019 Q1 | - INR | 0.0% |
| 2019 FY | 11.16 Million INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 FY | - INR | 0.0% |
| 2018 Q4 | - INR | 0.0% |
| 2018 Q3 | - INR | 0.0% |
| 2018 Q2 | - INR | 0.0% |
| 2017 Q4 | - INR | 0.0% |
| 2017 Q1 | - INR | 0.0% |
| 2017 Q2 | - INR | 0.0% |
| 2017 FY | - INR | 0.0% |
| 2016 FY | - INR | 0.0% |
| 2016 Q4 | - INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| 2014 FY | - INR | 0.0% |
| 2013 FY | - INR | 0.0% |
| 2012 FY | - INR | -100.0% |
| 2012 Q2 | 75 Million INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | 61.11 Million INR | 65.3% |
| 2010 FY | 36.97 Million INR | 167.85% |
| 2009 FY | 13.8 Million INR | 320.45% |
| 2008 FY | 3.28 Million INR | -96.12% |
| 2007 FY | 84.67 Million INR | 10.16% |
| 2006 FY | 76.86 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 97.779% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.935% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 90.537% |
| Granules India Limited | 689.71 Million INR | 97.975% |
| Indoco Remedies Limited | 3.51 Billion INR | 99.603% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | 94.061% |
| Alkem Laboratories Limited | 400 Million INR | 96.508% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -291.809% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | 49.82% |
| Bajaj HealthCare Limited | 650.34 Million INR | 97.852% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 96.076% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 99.767% |
| Eris Lifesciences Limited | 6.54 Billion INR | 99.787% |
| FDC Limited | 2.46 Million INR | -466.423% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 99.079% |
| Gufic Biosciences Limited | 1.53 Billion INR | 99.093% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 87.487% |
| Ipca Laboratories Limited | 5.8 Billion INR | 99.759% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 81.516% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 99.239% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 99.838% |
| Lupin Limited | 1.55 Billion INR | 99.1% |
| Mankind Pharma Limited | 248.67 Million INR | 94.383% |
| Medicamen Biotech Limited | 12.55 Million INR | -11.254% |
| Medico Remedies Limited | 8.67 Million INR | -61.07% |
| Megasoft Limited | 1.35 Billion INR | 98.971% |
| NATCO Pharma Limited | 53 Million INR | 73.645% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.944% |
| RPG Life Sciences Limited | -30.3 Million INR | 146.099% |
| Sigachi Industries Limited | 265.79 Million INR | 94.745% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -5.023% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 93.422% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 1245.857% |
| Unichem Laboratories Limited | 382.22 Million INR | 96.346% |
| Wanbury Limited | 820 Million INR | 98.297% |
| Windlas Biotech Limited | 20.18 Million INR | 30.783% |
| ZIM Laboratories Limited | 356 Million INR | 96.076% |
| Zydus Lifesciences Limited | 251 Million INR | 94.435% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 86.897% |
| Divi's Laboratories Limited | 20 Million INR | 30.16% |
| Hester Biosciences Limited | 1.81 Billion INR | 99.232% |
| Procter & Gamble Health Limited | 68.8 Million INR | 79.698% |
| Bal Pharma Limited | 363.82 Million INR | 96.161% |
| Strides Pharma Science Limited | 6.71 Billion INR | 99.792% |
| Venus Remedies Limited | 386.8 Million INR | 96.389% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -3392.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 99.004% |
| Shilpa Medicare Limited | 5.6 Billion INR | 99.751% |
| Aarti Drugs Limited | 2.75 Billion INR | 99.493% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 99.862% |
| Valiant Laboratories Limited | 746.63 Million INR | 98.129% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 94.091% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 98.68% |
| Themis Medicare Limited | 267.74 Million INR | 94.783% |
| Hikal Limited | 4.22 Billion INR | 99.67% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.913% |
| Sequent Scientific Limited | 1.42 Billion INR | 99.021% |
| Novartis India Limited | 50.7 Million INR | 72.45% |
| Wockhardt Limited | 8.91 Billion INR | 99.843% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.956% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 96.891% |
| Morepen Laboratories Limited | 33.64 Million INR | 58.478% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 89.54% |